Maraviroc

Registered South African indications:

• HIV-1  infection

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients

Cautions

• Breastfeeding
• Renal impairment
• Hepatic impairment
• Elderly
• Severe cardiovascular disease
• Risk of postural hypertension
• Underlying infections
• Underlying autoimmune disorders
• Non-CCR5 tropic HIV-1
• High body mass index
• Severe immunosuppression 
• Active tuberculosis
• Invasive fungal infections
• Hypersensitivity to peanut or soya

Forms avail. in SA and covered in this monograph: tab

HIV infection
- Treatment-experienced adult patients infected with only CCR5-tropic HIV-1 with evidence of viral replication
- HIV-1 strains resistant to multiple antiretroviral agents

• Oral (tab): See table below

Not established for use in children in South Africa

Consult HIV/infectious disease specialists prior to any decisions related to ARV regimen termination/switch

Pregnancy

• FDA Pregnancy Category B

Breastfeeding

• Caution; not recommended

Renal Impairment

• Caution; dose adjustment recommended

Hepatic Impairment

• Caution; no information available

Elderly

• Caution; no information available

Central Nervous System Disorders

• Depression
• Insomnia
• Seizures and seizure disorders

Cardiovascular Disorders

• Angina pectoris

Gastrointestinal Disorders

• Abdominal pain
• Nausea

Hepatobiliary Disorders

• Increased alanine aminotransferase 
• Increased aspartate aminotransferase 
• Hyperbilirubinaemia
• Increased gamma-glutamyltransferase
• Toxic hepatitis 
• Hepatic failure
• Hepatic cirrhosis
• Increased blood alkaline phosphatase

Genitourinary Disorders

• Renal failure
• Proteinuria

Endocrine and Metabolic Disorders

• Anorexia

Musculoskeletal Disorders

• Myositis
• Increased blood creatine phosphokinase 
• Muscle atrophy

Skin and Subcutaneous Tissue Disorders

• Rash
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis

Immune, Blood and Lymphatic System Disorders

• Anaemia
• Bile duct cancer
• Diffuse large B-cell lymphoma
• Hodgkin's disease
• Metastases to bone
• Metastases to liver
• Metastases to peritoneum
• Nasopharyngeal cancer
• Oesophageal carcinoma
• Pancytopenia
• Granulocytopenia

• Alcohol
• Cobicistat
• CYP3A4 inhibitors
• CYP3A4 inducers
• Efavirenz
• Elvitegravir
• Ritonavir
• Etravirine
• Boceprevir
• Telaprevir
• HIV protease inhibitors
• Non-nucleotide reverse transcriptase inhibitors
• Rifampicin
• Rifabutin
• Clarithromycin
• Telithromycin
• Carbamazepine
• Phenobarbital
• Phenytoin
• Ketoconazole
• Itraconazole
• St John's wort

Hepatic function

Maraviroc is a member of a therapeutic class called CCR5 antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5, preventing CCR5-tropic HIV-1 from entering cells.

Tablet 150mg

• Celsentri (GSK) originator

Tablet 300mg

• Celsentri (GSK) originator